FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511591917> ?p ?o ?g. }

• W2511591917 endingPage "140.e4" @default.
• W2511591917 startingPage "129" @default.
• W2511591917 abstract "Background The CONCERT study (observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab) aimed to describe patient characteristics, bevacizumab use, its efficacy in terms of progression-free survival (PFS) and overall survival (OS), and its safety in patients with metastatic colorectal cancer (mCRC) treated in daily medical practice. Patients and Methods CONCERT was an observational, prospective, multicenter, cohort study conducted in France. Patients with mCRC initiating bevacizumab combined with chemotherapy were included and followed up for ≤ 36 months. Results Overall, 737 evaluable patients were assessed, and 71%, 21%, and 8% initiated bevacizumab as first-, second-, or third-line therapy or more, respectively. Their mean age was 64.5 years (range, 25-88 years), and 60% were men. Bevacizumab was mainly started at 5 mg/kg every 2 weeks (95%) and mostly combined with FOLFIRI (leucovorin, 5-fluorouracil, irinotecan; 68.0%) or FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin; 22.0%). The median PFS was 10.4 months (95% confidence interval [CI], 9.6-11.3) in first-line, 8.5 months (95% CI, 7.0-9.2) in second-line, and 6.3 months (95% CI, 4.5-8.9) in third-line or beyond. The corresponding median OS was 25.3 months (95% CI, 21.5-28.6), 19.1 months (95% CI, 15.7-22.6), and 14.9 months (95% CI, 11.6-20.4). In first-line treatment, primary tumor resection and oxaliplatin-based chemotherapy were prognostic of a longer PFS. Eastern Cooperative Oncology Group performance status ≥ 2, > 1 metastatic sites, and intermediate or high risk using the Köhne prognostic index were associated with shorter PFS. The safety profile of bevacizumab combined with chemotherapy was comparable to that found by other observational studies of mCRC. Conclusion The efficacy and safety results of bevacizumab plus chemotherapy as first- and second-line treatment of mCRC in daily practice in the CONCERT observational, prospective study were in line with those from randomized clinical studies." @default.
• W2511591917 created "2016-09-16" @default.
• W2511591917 creator A5007810585 @default.
• W2511591917 creator A5013377092 @default.
• W2511591917 creator A5030078141 @default.
• W2511591917 creator A5054195758 @default.
• W2511591917 creator A5085121407 @default.
• W2511591917 creator A5091592799 @default.
• W2511591917 date "2017-06-01" @default.
• W2511591917 modified "2023-10-18" @default.
• W2511591917 title "Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT)" @default.
• W2511591917 cites W1970391226 @default.
• W2511591917 cites W2014590712 @default.
• W2511591917 cites W2019154519 @default.
• W2511591917 cites W2021462110 @default.
• W2511591917 cites W2033918240 @default.
• W2511591917 cites W2038537636 @default.
• W2511591917 cites W2076886613 @default.
• W2511591917 cites W2085705101 @default.
• W2511591917 cites W2098737602 @default.
• W2511591917 cites W2101711321 @default.
• W2511591917 cites W2105576289 @default.
• W2511591917 cites W2106885867 @default.
• W2511591917 cites W2125447919 @default.
• W2511591917 cites W2139945713 @default.
• W2511591917 cites W2143743735 @default.
• W2511591917 cites W2146530991 @default.
• W2511591917 cites W2149071817 @default.
• W2511591917 cites W2150887511 @default.
• W2511591917 cites W2156575195 @default.
• W2511591917 cites W2157410007 @default.
• W2511591917 cites W2157769714 @default.
• W2511591917 cites W2162731664 @default.
• W2511591917 cites W2165741055 @default.
• W2511591917 cites W2171790106 @default.
• W2511591917 cites W2277975170 @default.
• W2511591917 doi "https://doi.org/10.1016/j.clcc.2016.07.013" @default.
• W2511591917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28277294" @default.
• W2511591917 hasPublicationYear "2017" @default.
• W2511591917 type Work @default.
• W2511591917 sameAs 2511591917 @default.
• W2511591917 citedByCount "13" @default.
• W2511591917 countsByYear W25115919172017 @default.
• W2511591917 countsByYear W25115919172018 @default.
• W2511591917 countsByYear W25115919172019 @default.
• W2511591917 countsByYear W25115919172020 @default.
• W2511591917 countsByYear W25115919172021 @default.
• W2511591917 countsByYear W25115919172022 @default.
• W2511591917 countsByYear W25115919172023 @default.
• W2511591917 crossrefType "journal-article" @default.
• W2511591917 hasAuthorship W2511591917A5007810585 @default.
• W2511591917 hasAuthorship W2511591917A5013377092 @default.
• W2511591917 hasAuthorship W2511591917A5030078141 @default.
• W2511591917 hasAuthorship W2511591917A5054195758 @default.
• W2511591917 hasAuthorship W2511591917A5085121407 @default.
• W2511591917 hasAuthorship W2511591917A5091592799 @default.
• W2511591917 hasConcept C121608353 @default.
• W2511591917 hasConcept C126322002 @default.
• W2511591917 hasConcept C141071460 @default.
• W2511591917 hasConcept C143998085 @default.
• W2511591917 hasConcept C2776694085 @default.
• W2511591917 hasConcept C2776705615 @default.
• W2511591917 hasConcept C2777802072 @default.
• W2511591917 hasConcept C2778260052 @default.
• W2511591917 hasConcept C2780259306 @default.
• W2511591917 hasConcept C2780456651 @default.
• W2511591917 hasConcept C2780739268 @default.
• W2511591917 hasConcept C2780962732 @default.
• W2511591917 hasConcept C526805850 @default.
• W2511591917 hasConcept C71924100 @default.
• W2511591917 hasConcept C72563966 @default.
• W2511591917 hasConceptScore W2511591917C121608353 @default.
• W2511591917 hasConceptScore W2511591917C126322002 @default.
• W2511591917 hasConceptScore W2511591917C141071460 @default.
• W2511591917 hasConceptScore W2511591917C143998085 @default.
• W2511591917 hasConceptScore W2511591917C2776694085 @default.
• W2511591917 hasConceptScore W2511591917C2776705615 @default.
• W2511591917 hasConceptScore W2511591917C2777802072 @default.
• W2511591917 hasConceptScore W2511591917C2778260052 @default.
• W2511591917 hasConceptScore W2511591917C2780259306 @default.
• W2511591917 hasConceptScore W2511591917C2780456651 @default.
• W2511591917 hasConceptScore W2511591917C2780739268 @default.
• W2511591917 hasConceptScore W2511591917C2780962732 @default.
• W2511591917 hasConceptScore W2511591917C526805850 @default.
• W2511591917 hasConceptScore W2511591917C71924100 @default.
• W2511591917 hasConceptScore W2511591917C72563966 @default.
• W2511591917 hasIssue "2" @default.
• W2511591917 hasLocation W25115919171 @default.
• W2511591917 hasLocation W25115919172 @default.
• W2511591917 hasOpenAccess W2511591917 @default.
• W2511591917 hasPrimaryLocation W25115919171 @default.
• W2511591917 hasRelatedWork W1999397682 @default.
• W2511591917 hasRelatedWork W2014637687 @default.
• W2511591917 hasRelatedWork W2119775393 @default.
• W2511591917 hasRelatedWork W2120009106 @default.
• W2511591917 hasRelatedWork W2134986421 @default.
• W2511591917 hasRelatedWork W2159303174 @default.
• W2511591917 hasRelatedWork W2417717847 @default.

• next